Search results
Results From The WOW.Com Content Network
CHS is a paradoxical syndrome characterized by hyperemesis (persistent vomiting), as opposed to the better known antiemetic properties of cannabinoids. [15] The most prominent CHS symptoms are cyclical nausea, vomiting, and abdominal pain, concomitant with chronic cannabinoid use. [15]
This syndrome is characterized by nausea, cyclical vomiting, and cramping abdominal pain resulting from prolonged, frequent cannabis use. Standard first-line antiemetics such as ondansetron and prochlorperazine are often ineffective in treating cannabinoid hyperemesis syndrome. [26]
Psychosis, cannabis hyperemesis syndrome, and lung damage are uncommon, yet dangerous, reactions after ingesting or smoking cannabis. Rare marijuana side effects, from uncontrollable vomiting to ...
Treatment of neurological disorders, including tic disorders such as Tourette syndrome, and chorea; Treatment of severe nausea and emesis in postoperative and palliative care, especially for palliating adverse effects of radiation therapy and chemotherapy in oncology. Also used as a first line antiemetic for acute cannabinoid hyperemesis syndrome.
An antiemetic is a drug that is effective against vomiting and nausea. Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general anaesthetics, and chemotherapy directed against cancer. They may be used for severe cases of gastroenteritis, especially if the patient is dehydrated. [1] [2]
Long-term cannabis users are at risk for developing cannabinoid hyperemesis syndrome (CHS), characterized by recurrent bouts of intense vomiting and abdominal cramping during or within 48 hours of heavy cannabis use. [112] The mechanism behind CHS is poorly understood and is contrary to the antiemetic properties of cannabis and cannabinoids.
Cyclic vomiting syndrome (a poorly understood condition with attacks of vomiting) Cannabinoid hyperemesis syndrome (similar to cyclic vomiting syndrome, but has cannabis use as its underlying cause). High doses of ionizing radiation sometimes trigger a vomit reflex. Violent fits of coughing, hiccups, or asthma; Anxiety; Depression
While dronabinol was initially approved by the United States Food and Drug Administration (FDA) on May 31, 1985, [21] it was not until May 13, 1986, the Drug Enforcement Administration (DEA), issued a Final Rule and Statement of Policy authorizing the "rescheduling of synthetic dronabinol in sesame oil and encapsulated in soft gelatin capsules from Schedule I to Schedule II" (DEA 51 FR 17476-78).